Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ABCL

AbCellera Biologics Inc.

Healthcare | Biotechnology
$5.09 -0.17 (-3.23%) as of 2026-07-15 03:04 UTC
Market Cap$1.5B
Volume3.65M
EPS (TTM)$-0.49

AbCellera Biologics Inc. (NASDAQ: ABCL) is a $1.5B biotechnology company trading at $5.09 (−3.2% today). Figures from SEC EDGAR and market feeds; updated 2026-07-15 03:04 UTC.

52-Week Range
Low $2.75High $6.79

What AbCellera Biologics Inc. does

AbCellera is a clinical-stage biotechnology company that develops antibody-based medicines targeting areas with significant unmet medical need. The company built a specialized platform over many years that enables it to tackle challenging targets such as complex transmembrane proteins, as well as novel formats like multispecifics and antibody-drug conjugates. Historically, AbCellera partnered with other companies to advance their drug programs while validating its platform; it has now shifted focus to building its own internal pipeline of drug candidates.

Summarized from AbCellera Biologics Inc.’s SEC filings · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.
Key facts
Quote
Price$5.09
Change (1D)-0.17 (-3.23%)
Market cap$1.5B
Volume3.65M shares
52-week range$2.75 – $6.79
Valuation
EPS (TTM)$-0.49
Price/book1.58×
Returns
52-week return+85.1%
Revenue, margins & earnings
FY2021 Net income: $153MFY2021 Taxes & interest: $51MFY2021 Operating costs: $171M$375MFY2021FY2022 Net income: $159MFY2022 Taxes & interest: $58MFY2022 Operating costs: $269M$485MFY2022FY2023: net loss $146M on revenue $38M$38MFY2023FY2024: net loss $163M on revenue $29M$29MFY2024FY2025: net loss $146M on revenue $75M$75MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-06
  • 2026-07-06Seely LynnA152,207—
  • 2026-07-06Sandor VictorA152,207—
  • 2026-06-12Montalbano John S.A111,701—
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • BAKER BROS. ADVISORS LP30,275,938$105.66M+10.0%
  • BAILLIE GIFFORD & CO10,422,966$52.43M+0.6%
  • Capital World Investors13,361,096$46.63M0.0%
View QoQ ownership changes →
Company news View all →
Questions this page answers

What does AbCellera Biologics Inc. do?

AbCellera is a clinical-stage biotechnology company that develops antibody-based medicines targeting areas with significant unmet medical need.

What is ABCL's valuation?

ABCL trades at $5.09, as of 2026-07-15.

When did ABCL last file with the SEC?

AbCellera Biologics Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-06. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-15 03:04 UTC. This page is also available as JSON at /api/data?ticker=ABCL and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ABCL and 3,500+ tickers.

Create a free account — keep ABCL
For your agent
GET /api/data?ticker=ABCL

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt